Imperagen raises $5 million to apply quantum physics, AI to enzyme engineering

A biotech company Imperagen announced Thursday’s $5 million ($6.7 million) funding round led by PXN Ventures, with participation from IQ Capital and Northern Gritstone. The company was founded in 2021 by scientists from the Manchester Institute of Biotechnology Dr. Andrew Currin, Dr. Tim Eyes, and Dr. Andy Almond and he came out of university.

The startup aims to advance enzyme engineering by making it faster, more efficient, and less expensive than the slow, physical, trial-and-error approach currently used.

Imperagen is using three core technologies as it aims to redefine enzyme engineering. In particular, it uses quantum physics simulations instead of trial-and-error enzyme modifications in the lab. Imperagen predicts different types of enzymes on the computer using advanced quantum physics that can analyze millions of mutations, the company said. It then translates this into its own AI models, trained on the enzyme problems that Imperagen wants to investigate. Finally, to maintain its AI models, Imperagen uses robots and automation to generate test data, which is fed back to the AI ​​model, in a process called closed-loop simulation.

Enzymes are very important in many industries, especially pharmaceuticals, because they are important in the production of drugs. Startups like Imperagen hope to speed up enzyme engineering because it can have a domino effect, creating, for example, faster and more efficient drug discovery. Enzymes are also used in areas such as food, biofuel, and agriculture. Permanent experts looking again to enzymes – and the AI ​​technologies around them – that manufacturing and industrial production become sustainable.

Others on the site include Biomatter, Cradle Bio, and Absci.

On Thursday, Imperagen also announced that Guy Levy-Yurista will take over as CEO. Speaking to TechCrunch, he said that currently, the process of enzyme production is slowing down, where even new AI-based technologies can be trial and error but fail in industrial applications.

Imperagen hopes that its technology will make enzyme development “faster, more reliable, and more commercially available, helping companies bring better bio-based products to market without the long delays and uncertainty that have held the field back,” TechCrunch said.

Levy-Yurista has a background in AI, life sciences, and business technology. Although the founders will remain at the company, Levy-Yurista was brought in to help develop its new technology, including the AI ​​architecture for biocatalysis (a process that accelerates chemical transformations using natural products such as enzymes), and to expand the basic AI process, commercial models, and industrial partnerships.

The company has raised $8.5 million ($11.42 million) to date and the new funding will be used to hire more AI experts, carry out research and development, expand its testing laboratory capabilities, and create a go-to-market project within the next two years.

“Ultimately, Imperagen hopes that the widespread use of synthetic enzymes will enable industries to produce products that are cleaner, safer and better for people and the planet, and for the companies that take them,” said Levy-Yurista.